Anja Haltner

12PUBLICATIONS

29CO-AUTHORS

Optical technologyMolecular medicineCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|May 14, 2026

Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye disease.

|Jul 10, 2025

Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.

Sarah Walsh, Anja Haltner, Meaghan Bartlett

|Mar 06, 2025

Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.

Elena Castro, Di Wang, Sarah Walsh

|Oct 19, 2024

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.

Elena Castro, Jenna Ellis, Samantha Craigie

|Oct 22, 2022

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

Tom Martin, Saad Z Usmani, Jordan M Schecter

|Jul 11, 2022

Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Luciano J Costa, Parameswaran Hari, Jesus G Berdeja

Pageof 2

Frequent Collaborators

Imtiaz A Samjoo

Chris Cameron

Evelyn Worthington

Frank Dahlke

Meaghan Bartlett

Jonathan Nazari

Becky Hooper

Elena Castro

William Deraedt

Sarah Walsh

Frequent Collaborators

Imtiaz A Samjoo

Chris Cameron

Evelyn Worthington

Frank Dahlke